drugset
drugset / Trial / NCT04131322

Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.

NCT04131322 ↗

Phase 4 Terminated 24 enrolled Andalusian Public Foundation for Health Research in Seville
RandomizedParallel-groupOpen-labelTreatment

Summary

Loss of response of the Adalimumab biosimilar compared with the original drug.

Timeline

Start
2019-10-10
Primary completion
2020-06-08
Completion
2020-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous

Indications

Crohn disease ulcerative colitis